Literature DB >> 10064075

A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation.

E Zorn1, T Hercend.   

Abstract

We have studied a case of human primary melanoma displaying the classical signs of a spontaneous regression in order to characterize potentially efficient anti-tumor T cell responses. In a previous series of experiments a unique TCR Vbeta16+ T cell was shown to be highly expanded at the tumor site. The corresponding clone was isolated in vitro and found to be a CD8+ cytotoxic T lymphocyte with a strong and selective cytolytic activity against the autologous tumor cell line. Here, we demonstrate that this predominant Vbeta16+ tumor-infiltrating lymphocyte recognizes a peptide encoded by a novel unconventional myosin class I gene. This peptide includes a mutation due to a single nucleotide substitution. The resulting Glu-->Lys replacement at position 911 of the coding sequence is critical to generate the recognized T cell epitope. These experiments demonstrate the existence of a natural tumor-specific cytolytic T cell response in a primary regressing human melanoma lesion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10064075     DOI: 10.1002/(SICI)1521-4141(199902)29:02<592::AID-IMMU592>3.0.CO;2-2

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  27 in total

Review 1.  "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer.

Authors:  Matthew R Buckwalter; Pramod K Srivastava
Journal:  Semin Immunol       Date:  2008-08-20       Impact factor: 11.130

Review 2.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

3.  Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction.

Authors:  Jan C Schmollinger; Robert H Vonderheide; Kara M Hoar; Britta Maecker; Joachim L Schultze; F Stephen Hodi; Robert J Soiffer; Ken Jung; Marcelo J Kuroda; Norman L Letvin; Edward A Greenfield; Martin Mihm; Jeffery L Kutok; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

4.  ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.

Authors:  F Stephen Hodi; Jan C Schmollinger; Robert J Soiffer; Ravi Salgia; Thomas Lynch; Jerome Ritz; Edwin P Alyea; Jihong Yang; Donna Neuberg; Martin Mihm; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

5.  Getting personal with neoantigen-based therapeutic cancer vaccines.

Authors:  Nir Hacohen; Edward F Fritsch; Todd A Carter; Eric S Lander; Catherine J Wu
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

Review 6.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor.

Authors:  Nisheeth Srivastava; Pramod K Srivastava
Journal:  PLoS One       Date:  2009-07-10       Impact factor: 3.240

8.  Immune rejection of mouse tumors expressing mutated self.

Authors:  Fei Duan; Yun Lin; Cailian Liu; Manuel E Engelhorn; Adam D Cohen; Michael Curran; Shimon Sakaguchi; Taha Merghoub; Stephanie Terzulli; Jedd D Wolchok; Alan N Houghton
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 9.  Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.

Authors:  Joseph Obeid; Yinin Hu; Craig L Slingluff
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

Review 10.  Specificity in cancer immunotherapy.

Authors:  Andrea Schietinger; Mary Philip; Hans Schreiber
Journal:  Semin Immunol       Date:  2008-08-05       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.